ReviewDrug safety1999
Comparative safety and tolerability of angiotensin II receptor antagonists.
Review in Drug safety, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 94 citations in OpenAlex.
- The Impact of Azilsartan Medoxomil Treatment (Capsule Formulation) at Doses Ranging From 10 to 80 mg: Significant, Rapid Reductions in Clinic Diastolic and Systolic Blood Pressure.Journal of clinical hypertension (Greenwich, Conn.) · 2017Trial
- Azilsartan in Patients With Mild to Moderate Hypertension Using Clinic and Ambulatory Blood Pressure Measurements.Journal of clinical hypertension (Greenwich, Conn.) · 2017Trial
- Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study.Clinical drug investigation · 2010Trial
- Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials.Journal of clinical hypertension (Greenwich, Conn.) · 2004Trial
- Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements.Journal of clinical hypertension (Greenwich, Conn.)Trial
- Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.Journal of clinical hypertension (Greenwich, Conn.)Trial
- Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment.Journal of clinical pharmacology · 2018Article
- A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.Vascular health and risk management · 2011Review
- Review
- Olmesartan medoxomil: current status of its use in monotherapy.Vascular health and risk management · 2006Review
- Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey.BMC cardiovascular disorders · 2005Article
- Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists.Journal of human hypertension · 2005Review
- Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.Drugs · 2004Review
- Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension.Clinical drug investigation · 2003Article
- Drug points: Dysgeusia and burning mouth syndrome by eprosartan.BMJ (Clinical research ed.) · 2002Article
- The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.Journal of human hypertension · 2002Article
- Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs.Journal of human hypertension · 2002Review
- Olmesartan: induced maculopapular rash.Indian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a very common disease and represents a major risk factor for cardiovascular adverse events such as stroke and heart failure. In recent years, a big effort has been put into detecting and treating patients with hypertension. Several classes of drugs acting by different pharmacological mechanisms can be chosen for the treatment of hypertension. However, the long term use of all anti-hypertensive agents is sometimes limited by the occurrence of adverse effects. Thanks to continuous pharmacological research, new compounds are regularly developed and become available in clinical practice. Recently, several new, nonpeptide, orally active angiotensin II receptor antagonists have reached the market. Today, these substances represent the most specific way to block the renin angiotensin system. Numerous studies have now demonstrated that these angiotensin II antagonists are as effective as ACE inhibitors, calcium antagonists, beta-blockers or diuretics in lowering blood pressure in patients with hypertension. Given the increasing use of angiotensin II receptor antagonists in the treatment of hypertension, it is important to review their safety and tolerability. Based on the actual level of knowledge, the striking feature of this class of agents is their favourable safety and tolerability profile which appears to be equivalent to that observed with placebo. Indeed, so far, no clear class-specific adverse effect has been attributed to the angiotensin II receptor antagonists. Thus, if angiotensin II antagonists prevent target organ damage and reduce the morbidity and mortality of patients with hypertension, they may well become a first-line treatment of hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.